Nothing To Sneeze At: Merck Considers An Over-The-Counter Version Of Singulair
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker is also weighing whether to find a partner for the Schering-Plough OTC unit it will soon acquire.
You may also be interested in...
Merck Wins Singulair Patent Battle With Teva
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
Merck Wins Singulair Patent Battle With Teva
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
Merck/Schering: The Next Wave Of Consolidation
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.